1McFarland J. Pathophysiology (idiopathic) thrombocytopenic 2. of platelet destruction in immune purpura. Blood Rev,2002,16 : 1-2.
2Portielje JE,Westendorp RG,Kluin-Nelemans HC,et al. Morbidity and mortality in adults with idiopathic thrombocytopenic puvpura. Blood ,2001,97:2549-2554.
3Wang T, Zhao H,Ren H, et al. Type 1 and type 2 T-cell profiles in idiopathic thrombocytopenic purpura. Haematologica, 2005, 90:914-923.
4Stasi R, Pagano A, Stipa E, et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood, 2001, 98:952-957.
5Arnold DM, Dentali F, Crowther MA, et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thromho- cytopenic purpura. Ann Intern Med, 2007, 146:25-33.
6Zaja F, Baccarani M, Mazza P, et al. Dexamethasone plus ritux- imab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thromhncytopenia. Blood, 2010, 115:2755-2762.
7Shan D, Ledbetter JA, Press OW. Signaling events involved in an- ti-CD20-induced apoptosis of malignant human B cells. Cancer hnmunol Immunother, 2000, 48:6734583.
8Sailler L. Rituximab off label use for difficult-to-treat auto-immune diseases : reappraisal of benefits and risk. Clin Rev Allergy Immu- nol, 2008, 34 : 103-110.
9Zaja F, Battista ML, Pirrotta MT, et al. Lower dose rituximab is active in adults patients with idiopathic thrombocytopenie purpu- ra. Haematologica ,2008,93:930-933.
10Stas R, DeL Poeta G, Stipa E, et al. Response to B-cell deple- ting therapy with rituximab reverts the abnormalities of T-cell sub- sets in patients with idiopathic thrombocytapenic purpura. Blood, 2007, 110:2924-2930.
